R. Furman

J. Gribben, E. Montserrat, F. Awan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Yoonjin Cho, John P Leonard, R. Ulrich, 2014, Blood.

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

J. Leonard, R. Elstrom, R. Furman, 2016, Clinical Epigenetics.

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

J. Byrd, F. Awan, A. Schuh, 2017 .

Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.

A. Zelenetz, M. Keating, S. O'brien, 2015 .

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

A. Zelenetz, I. Flinn, B. Coiffier, 2014 .

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Jeffrey A Jones, J. Byrd, I. Flinn, 2016 .

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Jeffrey A Jones, B. Cheson, M. Davids, 2016 .

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia.

J. Byrd, S. O'brien, J. Pagel, 2021, Blood.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Sun Ku Lee, M. Kersten, B. Cheson, 2019, The Lancet. Haematology.

Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).

J. Byrd, A. Johnson, S. Stilgenbauer, 2013 .

BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity.

J. Leonard, J. Buggy, R. Furman, 2012 .

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Jeffrey A Jones, B. Cheson, M. Davids, 2017 .

Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.

Jeffrey A Jones, J. Byrd, T. Kipps, 2017 .

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

A. Zelenetz, B. Cheson, T. Burns, 2018, Haematologica.

Idelalisib immune-related toxicity is associated with improved treatment response

G. Salles, Jennifer R. Brown, R. Chan, 2021, Leukemia & lymphoma.

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

A. Zelenetz, S. O'brien, Jennifer R. Brown, 2017, Leukemia.

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

J. Leonard, I. Flinn, S. de Vos, 2016, Blood advances.

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

J. Leonard, I. Flinn, S. Coutre, 2013 .

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

E. Kimby, J. Gribben, F. Bosch, 2008 .

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia

J. Byrd, I. Flinn, T. Kipps, 2019, British journal of haematology.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

J. Gribben, I. Flinn, C. Klein, 2019, Blood.

Frontline management of chronic lymphocytic leukemia.

R. Furman, 2017, Clinical advances in hematology & oncology : H&O.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

J. Byrd, U. Jaeger, C. Dearden, 2017, Blood.

Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

D. Rossi, G. Gaidano, N. Chiorazzi, 2016, Blood advances.

Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.

J. Leonard, F. Lee, D. Knowles, 2009 .

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

E. Kimby, J. Gribben, F. Bosch, 2010 .

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

M. Dyer, T. Kipps, S. Stilgenbauer, 2010 .

Venetoclax in Previously Treated Waldenström Macroglobulinemia

R. Advani, M. Davids, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Leonard, I. Flinn, K. Rai, 2014 .

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

J. Byrd, U. Jaeger, J. Delgado, 2014 .

Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.

Jeffrey A Jones, A. Pettitt, S. Stilgenbauer, 2016 .

Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

Jeffrey A Jones, J. Byrd, S. O'brien, 2016 .

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

J. Byrd, J. Moslehi, J. Pagel, 2020 .

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

G. Acton, M. Davids, S. O'brien, 2019, Blood.

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES

G. Acton, M. Davids, J. Pinilla-Ibarz, 2019, HemaSphere.

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

J. Byrd, K. Yamaguchi, S. O'brien, 2017 .

SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

A. Pagnani, D. Rossi, G. Gaidano, 2016, The Journal of clinical investigation.

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

S. Jagannath, S. Lonial, R. Kurzrock, 2013, Clinical Cancer Research.

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

J. Drachman, R. Furman, A. Forero-Torres, 2010, Leukemia & lymphoma.

CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia

M. J. Broekman, A. Marcus, R. Furman, 2007, Journal of Translational Medicine.

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

A. Zelenetz, A. Pettitt, B. Cheson, 2020, Haematologica.

Epigenetic evolution and lineage histories of chronic lymphocytic leukemia

Martin J. Aryee, Rafael C. Schulman, Kevin Y. Huang, 2019, Nature.

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

R. Advani, J. Winter, B. Cheson, 2008 .

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

J. Leonard, D. Goldenberg, A. Chadburn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Jeffrey A Jones, J. Gribben, I. Flinn, 2017 .

Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.

J. Leonard, I. Flinn, K. Rai, 2015 .

Management of chronic lymphocytic leukemia.

S. Stilgenbauer, R. Furman, C. Zent, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial

J. Byrd, U. Jaeger, T. Kipps, 2015 .

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Bruce D Cheson, R. Advani, J. Winter, 2014, Journal of Hematology & Oncology.

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Nancy Whiting, R. Advani, A. Younes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New developments in immunotherapy for non-Hodgkin’s lymphoma

J. Leonard, R. Furman, J. Ruan, 2005, Current oncology reports.

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

M. Sadelain, R. Brentjens, R. Furman, 2018, Blood.

Current trends in the management of Richter's syndrome

R. Furman, J. Allan, 2018, International journal of hematologic oncology.

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.

J. Leonard, R. Elstrom, R. Furman, 2008, Seminars in hematology.

Immunotherapy of B-cell malignancies: first MABs, now SMIPs

J. Leonard, R. Furman, 2007 .

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

R. Advani, A. Younes, J. Drachman, 2006 .

Outcomes in CLL patients with NOTCH1 regulatory pathway mutations

P. Christos, E. Bhavsar, R. Furman, 2021, American journal of hematology.

Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia

R. Furman, T. Graef, E. Bilotti, 2017, Leukemia & lymphoma.

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

R. Advani, J. Leonard, C. Hofmeister, 2010 .

Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia

R. Advani, M. Davids, S. Treon, 2018, Clinical Lymphoma Myeloma and Leukemia.

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

Jeffrey A Jones, J. Byrd, S. O'brien, 2015 .

Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).

M. Kersten, P. Zinzani, E. Kastritis, 2018 .

Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: A report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project Running Title: 57 cases of PML following rituximab therapy

J. Vose, L. Gordon, A. Zelenetz, 2016 .

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

J. Leonard, I. Flinn, T. Jahn, 2012 .

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Sonali M. Smith, J. Leonard, P. Christos, 2014 .

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jeffrey A Jones, J. Byrd, A. Zelenetz, 2017 .

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

J. Leonard, I. Flinn, K. Rai, 2013 .

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial.

A. Zelenetz, A. Pettitt, B. Cheson, 2020, Haematologica.

Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.

J. Leonard, I. Flinn, K. Rai, 2013 .

PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

M. Sadelain, A. Younes, R. Furman, 2019, Hematological Oncology.

CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL)

J. Vose, A. LaCasce, J. Leonard, 2007 .

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

S. Trudel, O. O’Connor, A. Goy, 2012, Clinical Cancer Research.

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement

J. Leonard, S. Vallabhajosula, S. Kroll, 2007, Leukemia & lymphoma.

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.

J. Leonard, Zhengming Chen, R. Furman, 2016, Clinical lymphoma, myeloma & leukemia.

A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

J. Byrd, T. Kipps, U. Jäger, 2013 .

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

C. Gisselbrecht, S. Horwitz, N. Bartlett, 2010 .

TOP-M Chemotherapy (Thiotepa, Oncovin [Vincristine], Prednisone, Mitoxantrone) Plus Rituximab for Marginal Zone Lymphoma.

J. Leonard, R. Furman, M. Coleman, 2004 .

Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial

Jeffrey A Jones, M. Hallek, S. Stilgenbauer, 2014 .

Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.

R. Furman, D. Hoelzer, 2007, Seminars in oncology.

Forodesine (FodosineTM), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

F. Ravandi, L. Isola, G. Iosava, 2005 .

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

V. Gandhi, R. Furman, S. Bantia, 2004 .

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

V. Gandhi, L. Isola, R. Furman, 2004 .

Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

B. Cheson, T. Burns, C. Nabhan, 2017 .

A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL.

J. Byrd, I. Flinn, J. Flynn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

S. de Vos, R. Furman, P. Barr, 2022, Blood.

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

M. Dyer, T. Kipps, S. Stilgenbauer, 2009 .

Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia.

J. Leonard, J. Gabrilove, R. Furman, 2004 .

Prophylactic Low-Dose Aspirin Is Effective as Antithrombotic Therapy in Patients Receiving Combination Thalidomide or Lenalidomide.

J. Leonard, R. Pearse, R. Furman, 2005 .

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

S. Ansell, A. Chanan-Khan, Liuyan Jiang, 2018, British journal of haematology.

Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy.

T. Kipps, W. Wierda, A. Österborg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL).

T. Kipps, W. Wierda, A. Österborg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).

F. Ravandi, R. Furman, D. Hoelzer, 2006 .

A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study.

R. Advani, A. Younes, J. Drachman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide, procarbazine, cyclophosphamide): Low-dose continuous metronomic multidrug therapy

J. Leonard, R. Furman, J. Ruan, 2007 .

Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial

B. Cheson, C. Nabhan, J. Pagel, 2018, American journal of hematology.

Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).

J. Leonard, S. Kroll, L. Kostakoglu, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

F. Eitner, C. Bedrosian, N. Sheerin, 2011 .

Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans

Dennis P. Robinson, J. Cerhan, C. Vachon, 2021, Leukemia.

Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity

J. Leonard, R. Elstrom, R. Pearse, 2012, American journal of hematology.

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

S. Rafii, J. Leonard, E. Feldman, 2006 .

A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement.

J. Leonard, S. Kroll, L. Kostakoglu, 2004, Journal of Clinical Oncology.

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.

A. Zelenetz, I. Flinn, B. Coiffier, 2014 .

CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.

R. Kurzrock, H. Borghaei, R. Orlowski, 2006 .

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

C. Hofmeister, A. Chanan-Khan, Kelvin P Lee, 2009 .

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

J. Byrd, B. Cheson, M. Davids, 2019, Haematologica.

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY

S. Rule, R. Furman, M. Minnema, 2022, HemaSphere.

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma

J. Leonard, T. Fahey, R. Elstrom, 2008, Leukemia & lymphoma.

21 SF3B1 MUTATIONS INDUCE ABERRANT SPLICING LEADING TO A BLOCK IN ERYTHROID DIFFERENTIATION AND COMPETITIVE ADVANTAGE

B. Ebert, M. Warmuth, Shouyong Peng, 2015 .

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2012 .

5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B)

J. Byrd, J. Leonard, I. Flinn, 2011 .

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A. Zelenetz, J. Leonard, I. Flinn, 2013 .

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy

D. Rossi, G. Gaidano, R. Moia, 2023, Haematologica.

SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

A. Pagnani, D. Rossi, G. Gaidano, 2016, The Journal of clinical investigation.

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

Jeffrey A Jones, B. Cheson, M. Davids, 2017 .

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, I. Flinn, 2013, The New England journal of medicine.

LYMPHOID NEOPLASIA Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jeffrey A Jones, M. Caligiuri, A. Johnson, 2013 .

Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors.

M. Charlson, R. Elstrom, R. Furman, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Jeffrey A Jones, J. Byrd, N. Heerema, 2014, The Lancet. Oncology.

A rare complex rearrangement in the β -globin gene cluster causing a novel homozygous

E. Bhavsar, R. Furman, G. Abu-Zeinah, 2021 .

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

J. Drachman, R. Furman, A. Forero-Torres, 2010, Leukemia & lymphoma.

Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L

J. Leonard, W. Tam, S. Dillon, 2012, The Journal of Immunology.

J. Leonard, W. Tam, S. Dillon, 2022 .

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

M. Dyer, T. Kipps, S. Stilgenbauer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

J. Byrd, B. Linghu, F. Awan, 2019, Blood advances.

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

J. Leonard, S. Schuster, B. Shah, 2023, Blood advances.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Sonali M. Smith, J. Leonard, P. Christos, 2015, The New England journal of medicine.

A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.

J. Byrd, I. Flinn, L. Andritsos, 2009 .

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

S. Chen‐Kiang, R. Elstrom, R. Furman, 2008, Annals of Oncology.

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial

A. Zelenetz, I. Flinn, B. Coiffier, 2014 .

Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years in a Large Cohort of Patients Managed Primarily with Conservative Therapies.

J. Leonard, S. Ely, S. Chen‐Kiang, 2007 .

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

J. Leonard, I. Flinn, S. de Vos, 2016, Blood advances.

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

A. Chanan-Khan, S. Stilgenbauer, A. Kater, 2023, Blood.

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.

J. Leonard, Zhengming Chen, R. Furman, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).

P. Martin, R. Furman, M. Schuster, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

M. Davids, S. Chong, S. Pervaiz, 2023, Journal of Clinical Investigation.

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.

R. Furman, M. Bustoros, J. Castillo, 2023, Hematology/oncology clinics of North America.

Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

J. Leonard, F. Lee, D. Knowles, 2010, Clinical Cancer Research.

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma

S. Matthew, J. Leonard, E. Cesarman, 2008, British journal of haematology.

Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation

B. Ebert, M. Warmuth, K. Kunii, 2014 .

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

G. Salles, L. Sehn, A. Zelenetz, 2016 .

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

S. Lonial, R. Kurzrock, H. Borghaei, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL)

J. Leonard, S. Kroll, L. Kostakoglu, 2004 .

Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.

J. Byrd, S. O'brien, J. Pagel, 2020 .